Search

Displaying results 2511 - 2520 of 4591 in total
  1. Drug

    Tafamidis

    go.drugbank.com/drugs/DB11644
    ApprovedInvestigational

    Tafamidis and tafamidis meglumine (FX-1006A) are benzoxazole derivatives[A27206] developed by FoldRX.[A189717] Tafamidis is structurally similar to diflusinal.

  2. Drug

    Lanolin alcohols

    go.drugbank.com/drugs/DB14181
    Approved

    Lanolin alcohols are a complex combination of organic alcohols obtained by the hydrolysis of lanolin.

  3. Drug

    CCX915

    go.drugbank.com/drugs/DB05159
    Experimental

    CCX915 is developed by ChemoCentryx which targets the chemokine receptor CCR2 and is in phase 1 of clinical trial for the treatment of Multiple Sclerosis and Neurologic Disorders.

  4. Drug

    Olmesartan

    go.drugbank.com/drugs/DB00275
    ApprovedInvestigational

    [A175330] It was developed by Daiichi Sankyo Pharmaceuticals and approved in 2002.[A175345, L12882] … ARBs have been shown to have a protective effect on the heart by improving cardiac function, reducing afterload, increasing cardiac output and preventing ventricular hypertrophy and remodelling.

  5. Drug

    Lorcaserin

    go.drugbank.com/drugs/DB04871
    ApprovedInvestigationalWithdrawn

    It has been shown to reduce body weight and food intake in animal models of obesity, and it is thought that targeting the 5HT2C receptor may alter body weight by regulating satiety.

  6. Drug

    Vestronidase alfa

    go.drugbank.com/drugs/DB12366
    ApprovedInvestigational

    Vestronidase alfa, or vestronidase alfa-vjbk, is a recombinant human lysosomal beta glucuronidase that is a purified enzyme produced by recombinant DNA technology in a Chinese hamster ovary cell line. … In clinical trials, vestronidase alfa treatment demonstrated improvement and stabilization in motor symptoms by increasing the patients' ability to walk longer distances in comparison to treatment with

  7. Drug

    Dulaglutide

    go.drugbank.com/drugs/DB09045
    ApprovedInvestigational

    Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct … [A236070] Dulaglutide was initially approved by the FDA in 2014, and in February 2020 was approved for use in patients with T2DM and multiple cardiovascular risk factors for the prevention of cardiovascular

  8. Drug

    Leucovorin

    go.drugbank.com/drugs/DB00650
    ApprovedInvestigational

    [L56092, A257419] Unlike folic acid, leucovorin does not require the enzyme dihydrofolate reductase (DHFR) for activation, allowing it to function even when DHFR is inhibited by drugs like methotrexate

  9. Drug

    DaxibotulinumtoxinA

    go.drugbank.com/drugs/DB17929
    ApprovedInvestigational

    [A261075, L47860] DaxibotulinumtoxinA was first approved by the FDA on September 8, 2022, for the temporary improvement of glabellar lines.

  10. Drug

    Hydrogenated soybean oil

    go.drugbank.com/drugs/DB11302
    Approved

    Linolenic acid and stearic acids are contained in hydrogenated soybean oil, but hydrogenation results in reduced unsaturation in linolenic acid.